Stock News
Get Ready to Say Bye-Bye to SARS-CoV-2: Invivyd’s PEMGARDA Keeps Dominant Variants at Bay!
Welcome to the World of Pemivibart: A New Hope Against Viral Infectious Diseases Exciting News from Invivyd, Inc. September 3, 2024 Today, Invivyd, Inc. made a groundbreaking announcement regarding their continued efforts in the fight against serious viral infectious diseases. The new pseudovirus in vitro neutralization data revealed promising results for PEMGARDATM (pemivibart) and pipeline…
Breaking News: Plurilock Secures $1.1 Million Contract with U.S. Agency – Let’s Celebrate!
Unleashing the Power of Secure Cloud Solutions with Plurilock Picture this: you’re a forward-thinking organization looking to make a positive impact on a global scale. You want to collaborate faster, negotiate more efficiently, and ultimately, drive real change. But there’s a catch – you need a secure cloud solution that can keep up with your…
Unlocking the Power of Vulnerability: A Heartfelt Journey to Emotional Freedom
Theralase® Technologies Inc. Seeks Partnerships for Latest Discovery A Breakthrough in the Fight Against Herpes Simplex Virus Theralase® Technologies Inc. is making waves in the pharmaceutical world with its latest discovery, RuvidarTM. This lead drug formulation has been proven to be more effective in destroying the Herpes Simplex Virus 1 (HSV-1) than the current standard…
BeyondSpring Shines at 2024 Lung Cancer Conference: Oral Presentation and Two Poster Presentations at ESMO Congress Highlighting Revolutionary Anti-Cancer Treatment
BeyondSpring Inc. Announces Upcoming Presentations at Major Conferences Exciting News for Cancer Patients FLORHAM PARK, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, has some groundbreaking updates to share. The Company will be presenting final efficacy data…
Groundbreaking Study Reveals 62% Decrease in COVID-19 Mortality Rates with Opaganib: A Peer-Reviewed Publication
Improved Outcomes in COVID-19 Patients with Opaganib Data from a post hoc analysis of a randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia has revealed promising results. The analysis, published in the peer-reviewed journal Microorganisms, shows a 62% reduction in mortality and a 21% improvement in time to room air for…
Big News Alert: Calliditas Therapeutics Makes Moves After Asahi Kasei Drops Bombshell!
Big News in the Business World! Stockholm, September 3, 2024 By: Your Favorite Business Guru So, did you hear the latest buzz in the business world? Asahi Kasei Corporation has taken a bold move by acquiring more than 90 percent of the outstanding shares of Calliditas Therapeutics AB. They’re not stopping there – they want…
Join the Fun: Bionomics Takes the Stage at H.C. Wainwright’s 26th Annual Global Investment Conference!
Welcome to the Bionomics Blog! Exciting News from Bionomics Hey there, fellow science enthusiasts! Have you heard the latest news from Bionomics Limited? They just announced that they will be participating and presenting at the H.C. Wainwright 26th Annual Global Investment Conference! This conference is a big deal in the biotechnology world, and Bionomics will…
Investor Deadline Next Week: Robbins Geller Rudman & Dowd LLP Announces Opportunity for Walgreens Boots Alliance Inc. Investors with Substantial Losses to Lead Class Action Lawsuit
Charmingly Eccentric Blog: The Walgreens Class Action Lawsuit Introduction San Diego, September 03, 2024 – Robbins Geller Rudman & Dowd LLP recently announced that purchasers or acquirers of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) securities between October 12, 2023 and June 26, 2024, have until September 10, 2024 to seek appointment as lead plaintiff of…